Unicycive Therapeutics, Inc. P/S Ratio
The price-to-sales (P/S) ratio tells you how many dollars investors pay for each dollar of a company's annual revenue. It is market capitalization divided by revenue over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/S means investors are paying more for each dollar of sales; because revenue is rarely negative, the ratio stays usable for companies that are not yet profitable. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Unicycive Therapeutics, Inc. p/s ratio for the quarter ending 2023-12-31 was 446.94.
- Unicycive Therapeutics, Inc. p/s ratio for the quarter ending 2023-09-30 was 442.8.
- Unicycive Therapeutics, Inc. p/s ratio for the quarter ending 2023-06-30 was 119.94.
- Unicycive Therapeutics, Inc. p/s ratio for fiscal 2023 was 446.94.
- Available history
- 2023-06-30 to 2023-12-31
- Data captured
Historical P/S Ratio
Annual P/S Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |